ライフサイエンスコーパス: small-cell

1 ng, monophyletic radiation of organisms with small cells and genomes.

2 of several malignant human tumors, including small-cell and non-small cell lung carcinomas, glioma, n

3 The increased number of small cells below the guard cells and of fully developed

4 t T cell growth rates increase with size for small cells, but decrease with size for large cells.

5 ibits Cdr2 signaling to Wee1 specifically in small cells, but the time and place of their regulatory

6 Small cell carcinoma of the bladder (SCCB) is a rare and

7 cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type

8 Small cell carcinoma of the ovary, hypercalcemic type (S

9 f the SMARCA4 and SMARCA2 ATPase subunits in small cell carcinoma of the ovary, hypercalcemic type (S

10 to a mixture of tumor phenotypes, including small cell carcinoma, urothelial carcinoma, and squamous

11 adenocarcinoma, squamous cell carcinoma, and small cell carcinoma.

12 as, 7,426 squamous cell carcinoma, and 2,664 small-cell carcinoma cases) and 56,450 controls.

13 Cancer was diagnosed in 62% of the patients (small-cell carcinoma in 83%).

14 d patients with renal cell carcinoma and non-small-cell carcinoma.

15 associations were strongest for squamous and small cell carcinomas and weaker for adenocarcinoma.

16 influence the emerging collective motion of small cell cohorts.

17 body fluids often within exosomes, which are small cell-derived vesicles that function in intercellul

18 = 4), and management of clinical stage I non-small cell lung cancer (n = 1) were developed and modifi

19 dary to melanoma (n = 29 with 75 BMs) or non-small cell lung cancer (n = 11 with 32 BMs) treated with

20 dent cohort of patients with early-stage non-small cell lung cancer (N = 14), where the therapeutic e

21 Cultured human non-small cell lung cancer (NSCLC) A549 cells take up the pr

22 Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling

23 exclusively on the role of NF-kappaB in non-small cell lung cancer (NSCLC) and discuss its contribut

24 In non-small cell lung cancer (NSCLC) and prostate cancers, lin

25 hose silencing sensitized the human A549 non-small cell lung cancer (NSCLC) and SW620 colorectal canc

26 s where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personali

27 e development of targeted therapies with non-small cell lung cancer (NSCLC) being a paradigm for prec

28 or (EGFR) signaling is effective in some non-small cell lung cancer (NSCLC) but not in triple-negativ

29 he EGFR TKI osimertinib (AZD9291) in the non-small cell lung cancer (NSCLC) cell line H1975, which ha

30 pplied this approach to a KRAS-dependent non-small cell lung cancer (NSCLC) cell line, H23-KRAS(G12C)

31 A large panel of non-small cell lung cancer (NSCLC) cell lines (73 of 77) wer

32 samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced

33 Validation data: One set of public non-small cell lung cancer (NSCLC) data.

34 ion of platinum at the cellular level in non-small cell lung cancer (NSCLC) explant models after trea

35 ation of NADPH; however, its function in non-small cell lung cancer (NSCLC) has not been established.

36 Non-small cell lung cancer (NSCLC) have been reported to sec

37 Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis and

38 KRAS-mutant non-small cell lung cancer (NSCLC) is a major lung cancer su

39 A subset of non-small cell lung cancer (NSCLC) is driven by amplificatio

40 Non-small cell lung cancer (NSCLC) is known to have poor pat

41 EGFR inhibitor (EGFRi), osimertinib, in non-small cell lung cancer (NSCLC) is limited by acquired re

42 Non-small cell lung cancer (NSCLC) is often characterized by

43 Non-small cell lung cancer (NSCLC) is the deadliest form of

44 Non-small cell lung cancer (NSCLC) is the leading cause of c

45 Non-small cell lung cancer (NSCLC) is the most frequent subt

46 after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown.

47 timizing rheological parameters to print non-small cell lung cancer (NSCLC) patient derived xenograft

48 This platform was also tested using non-small cell lung cancer (NSCLC) patient samples, where an

49 9-2021), the majority (63%) of stage III non-small cell lung cancer (NSCLC) patients are prescribed w

50 Methods: Seventy-five non-small cell lung cancer (NSCLC) patients planned for lobe

51 ET/CT radiomics signature in early-stage non-small cell lung cancer (NSCLC) patients treated with ste

52 ls isolated from tumor tissue samples of non-small cell lung cancer (NSCLC) patients, and identify su

53 ct to (18)F-FDG PET response criteria in non-small cell lung cancer (NSCLC) patients.

54 R gene is commonly observed in tumors of non-small cell lung cancer (NSCLC) patients.

55 of local versus distant recurrences in a non-small cell lung cancer (NSCLC) population with mutated E

56 immunohistochemistry (IHC) on 8 pairs of non-small cell lung cancer (NSCLC) primary tumors and matche

57 g RNA (lncRNA) that are involved in male non-small cell lung cancer (NSCLC) radiation sensitivity.

58 ajority of miR-21-5p isolated from human non-small cell lung cancer (NSCLC) tissue possesses 3'-termi

59 ld potentiate the action of cisplatin in non-small cell lung cancer (NSCLC) treatment.

60 ed RNA aptamer (trans-RA16) that targets non-small cell lung cancer (NSCLC) was previously identified

61 ophages and monocytes from patients with non-small cell lung cancer (NSCLC) where c-MAF is overexpres

62 loped for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR-mutant tumors,

63 Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint in

64 In non-small cell lung cancer (NSCLC), accumulation of anti-inf

65 or types, including subsets of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid c

66 revalent in certain tumor types, notably non-small cell lung cancer (NSCLC), and associated with redu

67 have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level quanti

68 iotherapy is an option for patients with non-small cell lung cancer (NSCLC), distinguishing between N

69 While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments are

70 a (ERbeta) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alteratio

71 motherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance

72 division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common histolog

73 critical role for proline catabolism in non-small cell lung cancer (NSCLC).

74 ession program of de novo lipogenesis in non-small cell lung cancer (NSCLC).

75 ell integrity during clonal evolution in non-small cell lung cancer (NSCLC).

76 n treatment-naive patients with advanced non-small cell lung cancer (NSCLC).

77 e prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC).

78 utilized to treat solid tumors including non-small cell lung cancer (NSCLC).

79 er lobe is related with worse outcome of non-small cell lung cancer (NSCLC).

80 triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

81 for patients with advanced EGFR-mutant non -small cell lung cancer (NSCLC).

82 h-1 blockers is a promising modality for non-small cell lung cancer (NSCLC).

83 r survival particularly in patients with non-small cell lung cancer (NSCLC).

84 for different types of cancer, including non-small cell lung cancer (NSCLC).

85 rove accuracy of pulmonary resection for non-small cell lung cancer (NSCLC).

86 hibitors, respectively, in patients with non-small cell lung cancer (NSCLC).

87 is a major player in the pathogenesis of non-small cell lung cancer (NSCLC).

88 bitors and immune checkpoint blockade in non-small cell lung cancer (NSCLC).

89 has been applied to advanced metastatic non-small cell lung cancer (NSCLC).

90 the response to these agents in treating non-small cell lung cancer (NSCLC).

91 approach for several cancers, including non-small cell lung cancer (NSCLC).

92 ntiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor

93 Small cell lung cancer (SCLC) is a highly aggressive and

94 Small cell lung cancer (SCLC) is a highly aggressive mal

95 Small cell lung cancer (SCLC) is a highly aggressive sub

96 Small cell lung cancer (SCLC) is a neuroendocrine tumor

97 Small cell lung cancer (SCLC) is a recalcitrant, aggress

98 Small cell lung cancer (SCLC) is an aggressive form of l

99 Small cell lung cancer (SCLC) is an aggressive neuroendo

100 Small cell lung cancer (SCLC) is an exceptionally lethal

101 Small cell lung cancer (SCLC) is an understudied cancer

102 replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously trigg

103 In small cell lung cancer (SCLC), plasticity from NE to non

104 Applied to small cell lung cancer (SCLC), the workflow identifies f

105 dividually shown modest clinical activity in small cell lung cancer (SCLC).

106 rotein kinase A (PKA) as an active kinase in small cell lung cancer (SCLC).

107 dular regions of nodules can distinguish non-small cell lung cancer adenocarcinomas from benign granu

108 tracted imaging) features to distinguish non-small cell lung cancer adenocarcinomas from granulomas a

109 nd that combinatorial inhibitor treatment of small cell lung cancer and pancreatic cancer cell models

110 e progression of pre-invasive lesions in non-small cell lung cancer are poorly understood.

111 Using non-small cell lung cancer as a case study, we show that int

112 checkpoint kinase, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-mediated

113 We discovered that a subset of non-small cell lung cancer cells underwent a gradually progr

114 growth of K-Ras-addicted pancreatic and non-small cell lung cancer cells.

115 nzamide small molecule with activity against small cell lung cancer cells.

116 ovel mRNA degradation target of CNOT3 in non-small cell lung cancer cells.

117 and of treatment with erlotinib of PC-9 non-small cell lung cancer cells.

118 a 96-well automated workflow in a pilot non-small cell lung cancer classification study.

119 clusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and

120 a genetically engineered mouse model of non-small cell lung cancer driven by K-Ras G12D and p53 defi

121 S-986192 in patients with advanced-stage non-small cell lung cancer eligible for nivolumab treatment

122 Adults with non-small cell lung cancer followed from 30 days post-diagno

123 ed by deep learning in 100 patients with non-small cell lung cancer from the TRACERx cohort(6).

124 of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-direct

125 Systemic therapy for metastatic non-small cell lung cancer is selected according to the pres

126 s disease-free survival of patients with non-small cell lung cancer more accurately than clinical fea

127 or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the

128 TR is a promising therapy for the 10% of non-small cell lung cancer patients harboring mutations in S

129 Methods: Seventy-five non-small cell lung cancer patients planned for lobectomy we

130 PET/CT radiomic signature in early-stage non-small cell lung cancer patients treated with stereotacti

131 Non-small cell lung cancer remains a highly lethal malignanc

132 with the antifibrotic drug nintedanib in non-small cell lung cancer reported clinical benefits in ade

133 ctor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the

134 from real PET/CT scans of patients with non-small cell lung cancer served as model for three 3-dimen

135 ated with local control in patients with non-small cell lung cancer undergoing SBRT and could be comb

136 parative study of patients with advanced non-small cell lung cancer who received CPIs combined with C

137 ng (18)F-flortanidazole PET imaging in a non-small cell lung cancer xenograft model, we showed that m

138 ect of acute metformin administration on non-small cell lung cancer xenograft tumor hypoxia using PET

139 e-class problem ranged between 0.64 (for non-small cell lung cancer) and 0.82 (for melanoma); all P v

140 to those with the less aggressive form (non-small cell lung cancer).

141 ce of commonly observed mutated genes in non-small cell lung cancer, and their wild-type counterparts

142 (SMAPs) in Burkitt lymphoma, KRAS-driven non-small cell lung cancer, and triple-negative breast cance

143 t in both adeno and squamous subtypes of non-small cell lung cancer, as well as additional tumor indi

144 of care for many malignancies, including non-small cell lung cancer, but its benefits have not extend

145 of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regu

146 inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic str

147 o major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase inhib

148 kade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.

149 h poor clinical outcome in patients with non-small cell lung cancer, particularly those with lung ade

150 ti-PD-1-treated patients with metastatic non-small cell lung cancer, those with lower PD-1/PD-L1 inte

151 pancreatic cancer, colorectal cancer, or non-small cell lung cancer.

152 1) adnectin PET tracer, in patients with non-small cell lung cancer.

153 ates the initial treatment of metastatic non-small cell lung cancer.

154 adenocarcinoma, a pathologic subtype of non-small cell lung cancer.

155 roximately 20% of patients with advanced non-small cell lung cancer.

156 unmet need in the clinical diagnosis of non-small cell lung cancer.

157 rs magnitude lower than NSE cut-off value of small cell lung cancer.

158 d datasets of normal lung epithelium and non-small cell lung cancer.

159 vity in tumor tissues from patients with non-small cell lung cancer.

160 ation and tumorigenicity of KEAP1-mutant non-small cell lung cancer.

161 that CNOT3 is required for the growth of non-small cell lung cancer.

162 ead and neck squamous cell carcinoma and non-small cell lung cancer.

163 nclude breast, prostate, colorectal, and non-small cell lung cancer.

164 e evaluation of lung nodules and stage I non-small cell lung cancer.

165 hotopic immunocompetent murine models of non-small cell lung cancer: CMT167 (CMT) and Lewis lung carc

166 exes, occurs at very high frequencies in non-small cell lung cancers (NSCLC).

167 on, is elevated in both human and murine non-small cell lung cancers (NSCLC).

168 cific mutations characteristic of nearby non-small cell lung cancers (NSCLCs).

169 More than 90% of small cell lung cancers (SCLCs) harbor loss-of-function

170 nalysed the prognostic value of SASH1 in non-small cell lung cancers using publicly available dataset

171 f regulatory sites within the genomes of non-small cell lung cancers with a global scan for open chro

172 instability and as a predictive indicator of small cell lung cancers.

173 (34 male, 16 female, median age 73) with non-small cell lung carcinoma (NSCLC) and treated with ICI w

174 Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated rad

175 tegrated platform to detect and quantify non-small cell lung carcinoma (NSCLC) rare genetic mutants (

176 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were prospec

177 t human tumors, including small-cell and non-small cell lung carcinomas, glioma, neuroblastoma, and p

178 ivity than 10 mg/kg of docetaxel in A549 non-small cell lung, as well as MDA-MB-436 and SUM149 triple

179 cancerous agent against testicular, ovarian, small cell lung, colon and breast cancer in its liquid d

180 r former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on t

181 oside alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

182 itors for oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by act

183 nts with a confirmed diagnosis of either non-small-cell lung cancer (n=442) or small-cell lung cancer

184 either non-small-cell lung cancer (n=442) or small-cell lung cancer (n=81) were recruited.

185 made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung cance

186 ients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of t

187 The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against onco

188 personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-base

189 atients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or delaying

190 The majority of non-small-cell lung cancer (NSCLC) cases are diagnosed at ad

191 and selected resynthesized compounds in non-small-cell lung cancer (NSCLC) cells showed that cytotox

192 ol of ECT2 localizes to the nucleolus of non-small-cell lung cancer (NSCLC) cells, where it binds the

193 l specific function in regulating CME in non-small-cell lung cancer (NSCLC) cells.

194 Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefi

195 nagement of patients with advanced-stage non-small-cell lung cancer (NSCLC) in light of the ever-expa

196 st-line therapy for EGFR-mutant advanced non-small-cell lung cancer (NSCLC) is an epidermal growth fa

197 Non-small-cell lung cancer (NSCLC) is terminal in most patie

198 trial of pembrolizumab in patients with non-small-cell lung cancer (NSCLC) or melanoma with untreate

199 EGFR-mutant non-small-cell lung cancer (NSCLC) patients inevitably devel

200 omography (FDG-PET) response criteria in non-small-cell lung cancer (NSCLC) patients.

201 Non-small-cell lung cancer (NSCLC) represents approximately

202 disease in patients with oligometastatic non-small-cell lung cancer (NSCLC) that did not progress aft

203 imately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with

204 temic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver alteration

205 alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accur

206 of the head and neck (SCCHN), melanoma, non-small-cell lung cancer (NSCLC), or urothelial cancer.

207 In non-small-cell lung cancer (NSCLC), the functions of OPN hav

208 duration of immunotherapy, including for non-small-cell lung cancer (NSCLC).

209 regulator of acquired chemoresistance in non-small-cell lung cancer (NSCLC).

210 ic drivers of various cancers, including non-small-cell lung cancer (NSCLC).

211 o oxidative stress in vitro and in human non-small-cell lung cancer (NSCLC).

212 an important role in the development of non-small-cell lung cancer (NSCLC).

213 light on the role of the NF-kappaBeta in non-small-cell lung cancer (NSCLC).

214 ntenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC).

215 atients with previously treated advanced non-small-cell lung cancer (NSCLC).

216 oscopic (VATS) lobectomy for early stage non-small-cell lung cancer (NSCLC).

217 the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC).

218 pounds that inhibit the proliferation of non-small-cell lung cancer (NSCLC).

219 obstacle to the successful treatment of non-small-cell lung cancer (NSCLC).

220 options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-lin

221 ndependent predictors for the development of small-cell lung cancer (SCLC) in LEMS patients in multiv

222 Small-cell lung cancer (SCLC) is an aggressive form of l

223 fficiency for tumor-specific cytotoxicity in small-cell lung cancer (SCLC), a neuroendocrine carcinom

224 ay activation in adult solid tumors, such as small-cell lung cancer (SCLC), is unknown.

225 or patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively.

226 utated in highly aggressive tumors including small-cell lung cancer (SCLC), where its loss, along wit

227 uding non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

228 d myocardial infarction in patients with non-small-cell lung cancer (two [7%] of 27 patients), and co

229 ere the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer,

230 ival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit

231 t of patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations.

232 d expanding to all histological types of non-small-cell lung cancer and to add focus on immunotherapy

233 29dL) significantly suppressed the growth of small-cell lung cancer cell (H526) xenografts in mice.

234 glucose consumption and use it to screen non-small-cell lung cancer cell lines against bioactive smal

235 Transformed non-small-cell lung cancer cells, which maintain high glycol

236 from chemotherapy-naive individuals with non-small-cell lung cancer identified the transcription fact

237 sure mitochondrial membrane potential in non-small-cell lung cancer in vivo using a voltage-sensitive

238 mal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in canc

239 nation of the AR RTK fusion landscape in non-small-cell lung cancer is lacking.

240 0 clear-cell renal cell carcinoma and 99 non-small-cell lung cancer patients and identify both conser

241 Approximately 25% of all patients with non-small-cell lung cancer present with resectable stage IB-

242 -oesophageal junction adenocarcinoma and non-small-cell lung cancer were also enrolled (in two additi

243 ctal cancer were excluded; patients with non-small-cell lung cancer were later excluded in an amendme

244 the second year in patients with stage I-III small-cell lung cancer who have undergone curative-inten

245 untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutati

246 ors (ICIs) hold promise in patients with non-small-cell lung cancer without druggable mutations and i

247 ically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or ALK a

248 ents with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK a

249 cancer, those with the most aggressive form (small-cell lung cancer) had masculinized (low) Delta2D:4

250 othelial cancers and < 6% for pancreatic and small-cell lung cancer).

251 ommittee on Cancer-defined stage IB-IIIA non-small-cell lung cancer, an Eastern Cooperative Oncology

252 nic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers.

253 tro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma.

254 in the basket dose-expansion cohort (12 non-small-cell lung cancer, five gynaecological malignancy,

255 om (1) studies in patients with advanced non-small-cell lung cancer, FLAURA (osimertinib, n = 279; co

256 cally documented stage III, unresectable non-small-cell lung cancer, for which they had received at l

257 lder, had stage IV or recurrent squamous non-small-cell lung cancer, had previously been treated with

258 ost frequently mutated version of RAS in non-small-cell lung cancer, KRAS(G12C), we have the opportun

259 cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial

260 mune checkpoint inhibitors in metastatic non-small-cell lung cancer, we designed a trial to test the

261 c, MET-amplified, EGFR mutation-positive non-small-cell lung cancer, who had progressed on EGFR TKIs.

262 ntial neoadjuvant regimen for resectable non-small-cell lung cancer, with a high proportion of patien

263 or patients with metastatic non-squamous non-small-cell lung cancer.

264 rain metastases from EGFR and ALK mutant non-small-cell lung cancer.

265 cer; metastatic gastric cancer; and relapsed small-cell lung cancer.

266 used in treatments for ovarian, breast, and small-cell lung cancer.

267 immune checkpoint inhibitors in melanoma and small-cell lung cancer.

268 chemotherapy as first-line treatment of non-small-cell lung cancer.

269 a first-line treatment for ALK-positive non-small-cell lung cancer.

270 ath ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer.

271 y, as first-line treatment of metastatic non-small-cell lung cancer.

272 therapy-naive patients with non-squamous non-small-cell lung cancer.

273 t need for better therapies for squamous non-small-cell lung cancer.

274 generation inhibitors targeting EGFR in non-small-cell lung cancer.

275 ker-driven therapy questions in squamous non-small-cell lung cancer.

276 s cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology

277 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)(1).

278 phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based doub

279 ction pressure in early-stage, untreated non-small-cell lung cancers that produces multiple routes to

280 8 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopa

281 Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compr

282 e-cell RNA sequencing in human and mouse non-small-cell lung cancers, we identify a cluster of dendri

283 as it was shown for BRAF in melanoma and non-small-cell lung cancers.

284 or the treatment of ROS1 fusion-positive non-small-cell lung cancers; histology-agnostic approvals ha

285 d correlated with Akt hyperactivation in non-small-cell lung carcinoma (NSCLC), promotes tumour devel

286 , SIX1 and SIX2 protected RAS/P53-driven non-small-cell lung carcinomas from inflammatory cell death

287 ells from freshly resected human primary non-small-cell lung tumors.

288 ith mesothelioma or ovarian, pancreatic, non-small-cell lung, and breast cancers, 1 had a complete re

289 ial, mesothelioma, neuroendocrine, salivary, small-cell lung, thyroid, and vulvar), progression on or

290 he initial tumor was consistent with a 59 mm small cell neuroendocrine cancer with a Ki-67 index of 8

291 Small-cell neuroendocrine cancers (SCNCs) are an aggress

292 We obtained high quality data from small cell number.

293 ors (i.e. AR-/NE-; DNPC) and (v) tumors with small cell or NE gene expression without AR activity (SC

294 ty, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phen

295 Because HIDE probes are small, cell-permeant molecules, they can visualize dual

296 miss salient biological features captured by small cell populations.

297 y rod dominated retina containing only a few small cell profiles in the photoreceptor layer that migh

298 distinct communities with small genomes and small cell sizes relative to those in ambient soils.

299 Gradient sensing is challenging for small cells, which can experience little difference in l

300 The Nanoarchaeota are small cells with reduced genomes that are found attached